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Summary
The effects of preceding endoscopic mucosal resection (EMR) on the efficacy and safety of 
radiofrequency ablation (RFA) for treatment of nodular Barrett’s esophagus (BE) is poorly 
understood. Prior studies have been limited to case series from individual tertiary care centers. We 
report the results of a large, multicenter registry. We assessed the effects of preceding EMR on the 
efficacy and safety of RFA for nodular BE with advanced neoplasia (high-grade dysplasia or 
intramucosal carcinoma) using the US RFA Registry, a nationwide study of BE patients treated 
with RFA at 148 institutions. Safety outcomes included stricture, gastrointestinal bleeding, and 
hospitalization. Efficacy outcomes included complete eradication of intestinal metaplasia (CEIM), 
complete eradication of dysplasia (CED), and number of RFA treatments needed to achieve CEIM. 
Analyses comparing patients with EMR before RFA to patients undergoing RFA alone were 
performed with Student’s t-test, Chi-square test, logistic regression, and Kaplan–Meier analysis. 
Four hundred six patients were treated with EMR before RFA for nodular BE, and 857 patients 
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were treated with RFA only for non-nodular BE. The total complication rates were 8.4% in the 
EMR-before-RFA group and 7.2% in the RFA-only group (P = 0.48). Rates of stricture, bleeding, 
and hospitalization were not significantly different between patients treated with EMR before RFA 
and patients treated with RFA alone. CEIM was achieved in 84% of patients treated with EMR 
before RFA, and 84% of patients treated with RFA only (P = 0.96). CED was achieved in 94% and 
92% of patients in EMR-before-RFA and RFA-only group, respectively (P = 0.17). Durability of 
eradication did not differ between the groups. EMR-before-RFA for nodular BE with advanced 
neoplasia is effective and safe. The preceding EMR neither diminished the efficacy nor increased 
complication rate of RFA treatment compared to patients with advanced neoplasia who had RFA 
with no preceding EMR. Preceding EMR is not associated with poorer outcomes in RFA.
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INTRODUCTION
Barrett’s esophagus (BE) is a premalignant condition characterized by the replacement of 
normal stratified squamous epithelium by intestinalized columnar epithelium.1–4 BE is 
associated with a markedly increased risk of esophageal adenocarcinoma, and the incidence 
of this cancer has increased approximately sixfold over the past four decades.5–9 
Radiofrequency ablation (RFA) is safe and effective for eradication of the non-nodular 
dysplastic BE.10,11 For BE with nodular lesions, endoscopic mucosal resection (EMR) is 
commonly used to remove focal, nodular areas before performing RFA to eradicate the 
remaining intestinal metaplasia or dysplasia.12,13
The effects of preceding EMR on the efficacy and safety of RFA remains poorly understood. 
Theoretically, the scarring of the esophagus and the associated change in compliance of the 
esophageal wall caused by the preceding EMR may impact the efficacy of RFA and increase 
the risk of stricture or other complication.14 Previous work has reported a markedly 
diminished complete eradication of intestinal metaplasia (CEIM) rate and an increased 
stricture rate among patients who underwent EMR before RFA.14 However, two other 
studies have shown no increase in stricture rate with preceding EMR, nor decrease in rates 
of complete ablation of intestinal metaplasia.4,15 Despite the common performance of EMR 
prior to RFA in clinical practice, our understanding of the safety and efficacy of this 
treatment is limited, especially as it pertains to experience outside academic tertiary referral 
centers.
The aims of this study were to assess the effects of preceding EMR on the efficacy and 
safety of RFA for nodular BE, and to compare outcomes of EMR followed by RFA to those 
of RFA alone, in a nationwide, multicenter registry of patients treated with RFA for BE.
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US RFA patient registry
The US RFA Patient Registry, a multicenter study reporting processes and outcomes of care 
for patients treated with RFA for BE, enrolled patients at 148 institutions in the United 
States (113 community based, 35 academic affiliated). The registry assessed clinical 
outcomes of patients undergoing treatment of BE with RFA using the HALO Ablation 
Systems (GI Solutions, Sunnyvale, CA, a subsidiary of Covidien), and was funded by 
Covidien, Inc. The registry did not mandate protocols for care but provided a framework for 
treatment and follow-up of patients with Barrett’s esophagus. All physicians participating in 
this registry (n = 320) either elected to use Western institutional review board (IRB) 
approval, for those institutions with their own IRB, obtained IRB approval through their 
respective institutions.
Patient eligibility
Patients were enrolled from July 2007 to July 2011. Patients were eligible for inclusion in 
the registry if: (i) they had endoscopic evidence of columnar metaplasia in the tubular 
esophagus with accompanying biopsies demonstrating intestinal metaplasia (IM), and (ii) 
they were candidates for RFA for BE. Histology was classified using standardized grading, 
including non-dysplastic BE (NDBE), indefinite for dysplasia (IND), low-grade dysplasia 
(LGD), high-grade dysplasia (HGD), intramucosal carcinoma (IMC), and invasive 
adenocarcinoma.12,16 Those patients who had previously received one or more treatments 
prior to enrollment had collection of retrospective data, with subsequent prospective 
collection of data for ensuing visits. Patients who had not yet undergone treatment were 
prospectively enrolled. For purposes of this analysis, we included all eligible registry 
patients with confirmed HGD or IMC.
Data collection and record retention
Demographic data, baseline histology, endoscopic findings, number of treatment sessions, 
ablation outcomes, and complications were collected. Data were entered on standardized 
case report forms through an Internet-based, secured data entry and processing system. Data 
were analyzed by investigators in the clinical epidemiology program at the University of 
North Carolina Center for Gastrointestinal Biology and Disease (T32 DK07634), who had 
complete access to the data.
Treatment protocol
Data collated from previous clinical trials were distributed to the sites as a guideline for the 
treatment and follow-up protocol. However, because this is a registry study, institutions and 
individual physicians were free to deviate from the treatment protocols suggested in the 
literature, depending on patient requirements and the institution’s standard of care. The 
suggested treatment protocol provided to sites has been previously described.3 Our 
standardized protocol suggested medical therapy with twice-daily proton pump inhibitors 
(PPIs) to minimize any baseline inflammatory changes of the esophageal mucosa and to 
decrease acid reflux prior to and throughout RFA treatment, unless the patient had a 
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documented history of antireflux surgery. The endoscopic resection device used to resect 
visible lesions varied by institution. RFA was recommended at 2 months after all visible 
lesions underwent successful EMR.
At the initial visit, patients were treated with one of two ablation devices: the HALO360 
Circumferential Ablation System or the HALO90 Focal Ablation System. The decision 
regarding device was based on the burden of disease (Barrett’s segments of >3 cm being 
generally best treated with the circumferential catheter), as well as operator preference. 
Recommended treatment protocols were based on previously published data.10
Follow-up protocol
Following the initial RFA treatment, repeat endoscopy at 2–3 month intervals was 
recommended, with additional circumferential or focal RFA treatment for any visible 
residual BE. If no visible BE was observed, four-quadrant biopsies every cm were 
recommended throughout the length of the pretreatment BE. If these biopsies demonstrated 
no BE on pathologic review, the patients entered endoscopic surveillance. Initial surveillance 
was recommended at 3 months for patients with HGD or 6 months for patients with NDBE, 
IND, or LGD. If follow-up biopsies revealed IM or dysplasia, recurrent treatment with RFA 
was recommended.
Adverse events were reported using standardized forms and terminology. Each site also 
complied with reporting guidelines for their institution regarding reporting adverse events to 
their IRB and Food and Drug Administration under the Medical Device Reporting regulation 
in 21 C.F.R. Part 803.
Outcomes
Safety outcomes include stricture formation, gastrointestinal (GI) bleeding, and 
hospitalization. A stricture was defined as a narrowing of the lumen requiring dilation. GI 
bleeding was considered clinically significant if it resulted in hospitalization or blood 
transfusion. All treated patients were included in the safety analysis. Complication rates 
were reported per patient for both patients who received EMR before RFA and for patients 
who received RFA only.
The rates of CEIM, complete eradication of dysplasia (CED), and the number of RFA 
sessions were determined to assess treatment efficacy. CEIM was defined as at least one 
biopsy session negative for IM at least 12 months after initial RFA treatment. CED was 
defined as the absence of dysplasia from biopsy specimens at least 12 months after initial 
RFA treatment. All review was performed by local pathologists; results were reported on a 
standardized pathology form which specifically queried for the presence of intestinal 
metaplasia and dysplasia.
The efficacy analysis included patients who had a biopsy performed 12 months or more after 
initial RFA treatment. Efficacy outcomes were reported for patients who received the EMR 
before RFA treatment and for patients who received RFA only.
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Statistical analysis was performed using Stata software (version 13.0; StataCorp LP, College 
Station, TX). For descriptive statistics, mean and standard deviations were reported for 
continuous variables, and percentages were reported for continuous variables. Comparative 
analyses were performed with Student’s t-test or the Wilcoxon rank sum test for continuous 
variables, and Pearson Chi-square test or Fisher exact test for categorical variables. Logistic 
regression analysis was performed to compare the efficacy and safety between the two 
groups. Kaplan–Meier analysis was used to generate the curves of durability of CEIM. Log-
rank test was used to compare the differences in durability between the two treatment 
groups. P-values less than 0.05 were considered statistically significant.
RESULTS
Demographics and clinical characteristics
A total of 5521 patients with BE were enrolled in the US RFA Patient Registry. The patients 
were treated with RFA by 320 physicians at 148 institutions. Of these patients, 1263 (23%) 
had pretreatment histology HGD or IMC, and thus were included in the safety analysis. One 
thousand eighty-five (86%) were male, 1190 (94%) were Caucasian, and 1054 (83%) had 
HGD, and 209 (17%) had IMC. Of these patients, 406 (32%) patients underwent EMR 
before RFA, and 857 (68%) patients had RFA only.
Compared to patients with RFA alone, patients with EMR before RFA had worse 
pretreatment histology (IMC, 38% vs. 6%, P < 0.001), shorter BE segments (mean, 4.6 vs. 
5.4 cm, P < 0.001), were less likely to be taking twice-daily PPIs (74% vs. 81%, P < 0.001), 
and were more likely to be treated at academic settings (62% vs. 53%, P = 0.003) (Table 1). 
Other baseline characteristics, such as age, gender, and race, were not statistically different 
between the two groups.
Safety outcomes
Complication rates among patients who had EMR before RFA were not different than RFA 
only (8.4% vs. 7.2%; P = 0.48). Stricture occurred in 29 patients (7.1%) treated with EMR 
before RFA compared with 52 patients (6.1%) treated with RFA only (P = 0.47). Three 
patients (0.7%) in the EMR-before-RFA group experienced clinically significant GI bleeding 
compared with eight patients (0.9%) in the RFA-only group. Of patients who underwent 
EMR before RFA, seven patients (1.7%) were hospitalized, compared with 11 patients 
(1.3%) who underwent RFA only. Rates of stricture, bleeding, and hospitalization were not 
significantly different between the two groups. No treatment-related deaths occurred in 
either group. Stratified by pretreatment histology, the complication rates among patients who 
had EMR before RFA and RFA only were also similar (Table 2). In the safety cohort, 
patients in the EMR-before-RFA group underwent slightly fewer total RFA treatment 
sessions compared with RFA-only group (2.8 vs. 3.2, P < 0.001). Logistic regression 
analysis was conducted to control for BE length, baseline histology, PPI compliance, and 
practice setting. Results showed that the stricture rate was not significantly different between 
the two groups (odds ratios [ORs] with 95% confidence intervals [CIs] were 1.4 (0.9–2.4), 
using RFA-only group as reference).
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Of the 1263 patients with HGD or IMC at baseline, 994 had biopsies performed 12 months 
or more after initial treatment and thus were included in the efficacy analysis. Of these 
patients, 331 had EMR before RFA, and 663 had RFA only. Patients treated with EMR 
before RFA had similar rates of CEIM and similar rates of CED, compared with those 
treated with RFA only (see Table 3). CEIM was achieved in 277 of patients (84%) who had 
EMR before RFA and 554 of patients (84%) who received RFA only (P = 0.96). CED was 
achieved in 312 patients (94%) who had EMR before RFA and 609 patients (92%) who 
received RFA only (P = 0.17). CEIM and CED rates were also stratified by pretreatment 
histology. When stratified, the CEIM and CED rates were comparable between the two 
treatment groups (Table 3). In the efficacy cohort, the number of total RFA sessions required 
for the EMR-before-RFA group was fewer than that for the RFA-only group (mean, 3.0 vs. 
3.5, P < 0.001). Controlling for BE length, baseline histology, PPI compliance and practice 
setting, neither CEIM rate nor CED rate was significantly different between the two groups 
(ORs with 95% CIs are 1.1 [0.8–1.5] and 1.3 [1.0–1.7], for CEIM and CED rate, 
respectively, using RFA-only as reference group.
Five out of 331 patients (1.5%) who had EMR before RFA progressed to invasive 
adenocarcinoma, whereas 24 out of the 663 patients (3.6%) who had RFA-only developed 
invasive adenocarcinoma (P = 0.07). Among the five patients in the EMR-before-RFA 
group, two (1.0%) patients progressed from HGD and three (2.4%) patients progressed from 
IMC. Among the 24 patients in the RFA-only group, 23 (3.7%) patients progressed from 
HGD and one (2.9%) patients progressed from IMC.
Durability outcomes
Among the patients who achieved CEIM, 165 out of 831 (19.9%) experienced a recurrence 
of IM, including 57 of 277 patients (21%) who were treated with EMR prior to RFA, and 
108 of 554 patients (19%) who were treated with RFA alone. The recurrence of IM were not 
significantly different (log-rank P = 0.96). The Kaplan Meier curves were shown in Figure 1.
DISCUSSION
We used the US RFA Registry to assess the effects of preceding EMR on the efficacy and 
safety of RFA for BE with advanced neoplasia, and to compare these patients to those who 
had RFA only for non-nodular BE with advanced neoplasia, in an effort to understand the 
impact of performing EMR prior to RFA. Both treatment techniques were found to be 
equally effective and safe. Among the 1263 patients in the safety group, approximately 7% 
of patients experienced complications, the most common being strictures. In the efficacy 
analysis of the 994 patients, the efficacy of EMR/RFA treatment was comparable to RFA 
alone with approximately 84% of patients achieving CEIM and >90% of patients achieving 
CED.
The impact of the preceding EMR on the efficacy and safety of the RFA treatment remains 
unclear, and previous data are conflicting. Several studies investigating the safety and 
efficacy of RFA for BE have included patients undergoing EMR, however, the lack of two 
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distinct groups (EMR-before-RFA and RFA alone) prevented comparison of their effects on 
the safety and efficacy.17–20 A study from the Mayo Clinic has reported a CEIM rate of only 
43% in EMR-before-RFA treatment group (n = 44) compared with 74% in RFA-only group 
(n = 46), suggesting that preceding EMR may diminish the efficacy of RFA.14 A second 
study from the Netherlands found that EMR was associated with a poor initial response to 
circumferential RFA, if that EMR resulted in regeneration of tissue that was Barrett’s, as 
opposed to a squamous island (OR 4.7; 95% CI 1.1–20.0).21 In contrast, a study from the 
University of North Carolina (UNC) reported no statistically significant differences in CEIM 
rates between EMR-before-RFA and RFA-only groups (n = 148; 88.0% vs. 77.6%, P = 
0.13).4 Studies from other western countries also reported comparable efficacy between the 
two groups.15,22 A recent study from the UK National Halo RFA Registry reported that the 
dysplasia clearance among patients underwent EMR before RFA to be comparable to that 
among patients treated with RFA alone (79% vs. 71%, P = 0.20).22 The results from a 
tertiary center in France, although limited by small number of patients (16 and 18 patients, 
respectively in each group), also suggested that EMR before RFA has not diminished the 
efficacy of RFA (56% vs. 44%, P = 0.73).15
The inconsistencies in the published results may be attributed to the limits of tertiary care 
single-center studies. These studies are subject to local expertise and individual assessment 
standards, were varied in pretreatment histology, and some were limited by small study 
populations. Because nodularity is more common among advanced neoplasia, we restricted 
our analysis to patients with pretreatment histology of high-grade dysplasia and 
intramucosal carcinoma to improve comparability between the nodular and non-nodular 
groups. In addition, we compared the efficacy and safety between the two groups by pre-
treatment histology to avoid potential confounding.
Complication rates of EMR performed in conjunction with RFA in the literature are varied. 
The Mayo Clinic study reported a stricture rate of 14% for EMR-before-RFA group and 9% 
for RFA-only group.14 The UK registry study also found that patients who underwent EMR 
before RFA were more likely to develop strictures compared to those who underwent RFA 
alone (12% vs. 5.9%; P = 0.04).22 However, in the UNC study, the stricture rate was not 
higher in the group with preceding EMR (4.6% in EMR/RFA vs. 7.7% in RFA alone, P = 
0.53).4 Our results are most consistent with the findings from this study, in that preceding 
EMR did not increase the risk of stricture or other complications.
Our study reported comparable durability of CEIM between the two groups (21% vs. 19%, P 
= 0.96). Consistent with our results, a US multicenter consortium study also reported 
durability of CEIM in subjects who had an EMR prior to RFA to be comparable to that of 
subjects who had RFA alone after controlling for age and gender (n = 229, OR = 1.18 [0.60, 
2.34], P = 0.62).23 Another US multicenter follow-up study reported that patients who 
underwent an EMR prior to RFA were actually more likely to maintain durable eradication 
of IMC/dysplasia (P = 0.03).24 However, these results may be subject to the small patient 
number (n = 36).
Our data have important implications for patient management. If patients with advanced 
neoplasia in BE and nodularity had only a 43% rate of CEIM, as reported by Okoro et al.,14 
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clinicians might be more likely to consider this therapy inadequate, opting instead for 
esophagectomy in patients with advanced neoplasia and nodularity. On the other hand, the 
higher rates of eradication reported in this study are reassuring that EMR, with resection of 
neoplasia to rule out the presence of submucosal disease, lymphovascular invasion or other 
characteristics of locally advanced disease, followed by RFA, is adequate therapy for these 
patients.
We found that the original BE length of patients treated with EMR before RFA was 
somewhat shorter than that of patients treated with RFA only (4.6 vs. 5.4 cm, P < 0.001). 
This small difference in baseline BE length was unlikely to have confounded our results. 
Recent studies have demonstrated that EMR with RFA was effective and safe in the 
treatment of BE independent of BE length, although more treatment sessions were required 
for treating longer BE segments.25,26 Consistent with these findings, our results have shown 
that fewer RFA sessions were performed in the EMR-before-RFA group compared with the 
RFA-only group (2.8 vs. 3.2, P < 0.001). Our multivariate regression analysis also suggest 
that both safety and efficacy are comparable between the two groups after controlling for BE 
length and other unbalanced distribution of demographic/clinical characteristics observed in 
Table 1.
Our study’s limitations must be noted. This study was strictly observational and treatment 
paradigms could not be mandated. While BE with nodularity and non-nodular BE are 
different conditions, comparison of the two groups allows inference of the effect of 
preceding EMR on subsequent RFA treatment. Additionally, given the size and nature of our 
study, no re-interpretation of pathological specimens by a central lab was possible, and local 
practices as to the histological interpretation were used. Another limitation of this study is 
the lack of information on the total mucosal area removed by EMR, which may have a 
potential effect on efficacy and stricture rates. Additionally, a small proportion of patients 
were enrolled retrospectively, which may potentially result in underestimation of 
complication rates and misclassification errors. However, given that the proportion of 
subjects with retrospective enrollment was non-differential between the nodular and non-
nodular groups, such errors would also be expected to be non-differential.
There are several strengths to our study. Our study is the largest cohort to date to assess the 
effects of EMR before RFA on the efficacy and safety outcomes of RFA. Our study is a 
nationwide, multicenter registry study, including both academic-affiliated and community-
based institutions. Therefore, our results are more representative of real-life practices and 
provide increased generalizability. Study definitions were a priori, and data were collected in 
a standardized fashion. Furthermore, our study addressed the effect of initial EMR on the 
efficacy and safety of RFA, an area with conflicting prior reports.
In summary, EMR-before-RFA for nodular BE is effective and safe for the treatment of BE 
with advanced neoplasia, and comparable in safety, efficacy and durability to RFA only for 
non-nodular BE in this largest reported cohort of patients.
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Kaplan–Meier analysis of durability of complete eradication of intestinal metaplasia 
(CEIM).
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Table 1
Safety cohort baseline characteristics
EMR before RFA (n = 406) RFA alone (n = 857) P-value
Age (mean ± SD, years) 67.2 ± 10.2 66.3 ± 10.4 0.14
Race, n (%)
 Caucasian 388 (95.6) 802 (93.6) 0.43
 Black 5 (1.2) 8 (0.9)
 Hispanic 5 (1.2) 13 (1.5)
 Asian/Pacific Islander/Other 1 (0.3) 5 (0.6)
 Unknown 7 (1.7) 29 (3.4)
Male gender, n (%) 350 (86) 735 (86) 0.83
Length of BE segment (mean ± SD, cm) 4.6 ± 3.6 5.4 ± 3.6 <0.001
Pre-treatment fundoplication, n (%) 15 (3.7) 31 (3.6) 0.95
Pre-treatment histology, n (%)
 High-grade dysplasia 252 (62) 802 (94) <0.001
 Intramucosal carcinoma 154 (38) 55 (6)
Taking twice daily PPI, n (%) 299 (74) 693 (81) 0.003
Treatment at an academic medical center, n (%) 252 (62) 457 (53) 0.003
Mean follow-up time (mean ± SD, years) 2.86 ± 1.53 2.76 ± 1.66 0.31
BE, Barrett’s esophagus; EMR, endoscopic mucosal resection; PPI, proton pump inhibitor; RFA, radiofrequency ablation; SD, standard deviation.
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Table 2
Safety outcomes
EMR before RFA RFA alone P-value
All patients, n (%) 406 857
 Any complication† 34 (8.4) 62 (7.2) 0.48
 Stricture 29 (7.1) 52 (6.1) 0.47
 Bleeding 3 (0.7) 8 (0.9) 0.73
 Hospitalization‡ 7 (1.7) 11 (1.3) 0.54
High-grade dysplasia, n (%) 252 802
 Any complication† 26 (10.3) 60 (7.5) 0.15
 Stricture 21 (8.3) 50 (6.2) 0.25
 Bleeding 3 (1.2) 8 (1.0) 0.79
 Hospitalization‡ 7 (2.8) 11 (1.4) 0.13
Intramucosal carcinoma, n (%) 154 55
 Any complication† 8 (5.2) 2 (3.6) 0.64
 Stricture 8 (5.2) 2 (3.6) 0.64
 Bleeding 0 0 –
 Hospitalization‡ 0 0 –
Total RFA treatments (mean ± SD) 2.8 ± 1.9 3.2 ± 2.0 <0.001
 Circumferential treatments 0.7 ± 0.8 0.9 ± 0.9 0.08
 Focal treatments 2.1 ± 1.6 2.4 ± 1.8 0.29
†
Some patients experience >1 complication;
‡
Hospitalizations were secondary to post-procedural hemorrhage. EMR, endoscopic mucosal resection; RFA, radiofrequency ablation; SD, 
standard deviation.
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Table 3
Efficacy outcomes
EMR before RFA RFA alone P-value
All patients, n (%) 331 663
 CED 312 (94) 609 (92) 0.17
 CEIM 277 (84) 554 (84) 0.96
High-grade dysplasia, n (%) 204 628
 CED 192 (94) 574 (92) 0.21
 CEIM 173 (85) 521 (83) 0.54
Intramucosal carcinoma, n (%) 127 35
 CED 120 (95) 35 (100) 0.16
 CEIM 104 (82) 33 (94) 0.07
Total RFA treatments, (mean ± SD) 3.0 ± 1.9 3.5 ± 2.1 <0.001
 Circumferential treatments 0.7 ± 0.8 0.9 ± 0.9 0.001
 Focal treatments 2.3 ± 1.7 2.6 ± 1.8 0.46
CED, complete eradication of dysplasia; CEIM, complete eradication of intestinal metaplasia; EMR, endoscopic mucosal resection; RFA, 
radiofrequency ablation; SD, standard deviation.
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